Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From Hodgkin Lymphoma / Systemic ALCL to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate (ADC) approved globally for classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL), though it is not currently marketed in Canada. The TxGNN model predicts it may be effective for Follicular Lymphoma, with 3 relevant clinical trials and several publications providing supporting evidence. Applicability is conditional on CD30 expression in individual cases, which is heterogeneous in follicular lymphoma and most prominent in relapsed or transformed disease.

Quick Overview

Item	Content
Original Indication	Classical Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma (sALCL)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L2
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not available from the current evidence pack. Based on published knowledge, brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody (brentuximab) chemically linked to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. Upon binding to CD30-expressing tumor cells, the complex is internalized and MMAE is released intracellularly, disrupting mitosis and triggering apoptosis. This targeted delivery mechanism has been validated in classical Hodgkin lymphoma — where Reed-Sternberg cells uniformly overexpress CD30 — and in systemic ALCL.

The theoretical bridge to follicular lymphoma (FL) rests on the observation that a subset of FL cases, particularly in the relapsed, refractory, or histologically transformed setting, can express CD30 on tumor cells. This aberrant surface expression creates a targetable window for BV, even though CD30 positivity in de novo FL is far lower than in HL or ALCL. The mechanistic rationale is therefore valid but population-restricted: BV’s activity in FL is expected to correlate tightly with the degree of CD30 expression, which requires prospective immunohistochemical testing to identify eligible patients.

The TxGNN prediction is further strengthened by the existence of a dedicated prospective Phase 2 trial (NCT04587687) designed explicitly for CD30+ relapsed/refractory FL, and by case-level evidence showing complete responses in FL that transformed to CD30+ lymphoma after BV-based therapy. The shared histological category of B-cell lymphoma between HL and FL also provides a degree of biological similarity that underpins model plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04587687	Phase 2	Recruiting	23	BV + bendamustine for relapsed/refractory follicular lymphoma; the only dedicated Phase 2 trial targeting CD30+ FL directly; results not yet published
NCT01805037	Phase 1/2	Terminated	20	BV + rituximab as frontline therapy for CD30+ and/or EBV+ lymphomas including FL subgroup; terminated early but provides safety and preliminary efficacy signals across B-cell histologies
NCT02594163	Phase 2	Terminated	25	Randomized trial of rituximab + bendamustine ± BV for relapsed/refractory CD30+ DLBCL; terminated early with 25 cases enrolled, offering indirect evidence on BV activity in CD30+ B-cell lymphomas

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32476657	2020	Case Report	Gulf Journal of Oncology	Grade I FL transformed to CD30+ ALK1− ALCL; complete response achieved with BV + high-dose methotrexate; demonstrates BV activity in FL after transformation to a CD30+ phenotype
35663281	2022	Review	Leukemia Research Reports	Review of immunotherapy in indolent NHL including FL; discusses emerging targeted agents and the rationale for CD30-directed therapy in select NHL subtypes
40758949	2025	Clinical Trial/Cohort	Blood Advances	LYSA Phase 2 study of BV + gemcitabine followed by BV maintenance in R/R PTCL patients with ≥5% CD30+ cells; provides contemporary data on BV efficacy in CD30-variable lymphomas
38306597	2024	Review	Blood	Current treatment landscape for nodal PTCLs; describes BV+CHP as standard of care for CD30+ disease and contextualizes CD30 expression thresholds for treatment selection
34797505	2022	Real-World Study	Advances in Therapy	Retrospective real-world analysis of BV + CHP in untreated CD30+ NHL (including PTCL-TFH and ALCL); high overall remission rates observed across CD30+ B- and T-cell histologies

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Antibody-Drug Conjugate (ADC) with cytotoxic microtubule-disrupting payload (MMAE)
Myelosuppression Risk	Moderate to High (neutropenia is among the most common grade 3/4 adverse events; febrile neutropenia reported in clinical trials)
Emetogenicity Classification	Low to Moderate (MMAE-based ADCs generally carry low emetogenic potential compared to conventional cytotoxic chemotherapy)
Monitoring Items	CBC with differential (prior to each cycle), liver function tests, renal function, peripheral neuropathy assessment (sensory and motor), pulmonary function if respiratory symptoms arise
Handling Protection	Required — must be prepared and administered under cytotoxic drug handling regulations; MMAE payload constitutes a hazardous agent

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: An active, dedicated Phase 2 trial (NCT04587687) targeting CD30+ relapsed/refractory follicular lymphoma is currently recruiting, demonstrating that the scientific community has endorsed this repurposing hypothesis sufficiently to fund prospective investigation. Combined with mechanistic plausibility (CD30 expression in transformed/relapsed FL) and indirect Phase 2 data from related B-cell lymphoma studies, there is sufficient evidence to advance this candidate into structured evaluation — but only for the CD30-positive FL subpopulation.

To proceed, the following is needed:

CD30 expression testing: Prospective immunohistochemistry (IHC) to confirm CD30 positivity in candidate patients; BV is unlikely to benefit CD30-negative FL cases
Results from NCT04587687: The ongoing Phase 2 trial is the critical data gap; monitoring its outcomes should be the first priority before any independent clinical expansion
Full mechanism of action documentation: DrugBank API query to formally document BV’s MOA for regulatory submission purposes
Safety data retrieval: Download and parse the full prescribing information/package insert (Health Canada or FDA) to populate the currently empty key warnings and contraindications fields
Drug interaction review: Conduct formal DDI screening for the Canadian formulary context, particularly interactions involving MMAE metabolism (CYP3A4 pathway)
Canadian regulatory pathway review: Assess whether Adcetris (BV) has a pending or completed Health Canada submission, as global approvals (FDA, EMA) exist and a regulatory bridging strategy may expedite Canadian access

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.